Back to Search Start Over

Development of graphitic carbon nitride quantum dots-based oxygen self-sufficient platforms for enhanced corneal crosslinking.

Authors :
Yang M
Chen T
Chen X
Pan H
Zhao G
Chen Z
Zhao N
Ye Q
Chen M
Zhang S
Gao R
Meek KM
Hayes S
Ma X
Li X
Wu Y
Zhang Y
Kong N
Tao W
Zhou X
Huang J
Source :
Nature communications [Nat Commun] 2024 Jun 29; Vol. 15 (1), pp. 5508. Date of Electronic Publication: 2024 Jun 29.
Publication Year :
2024

Abstract

Keratoconus, a disorder characterized by corneal thinning and weakening, results in vision loss. Corneal crosslinking (CXL) can halt the progression of keratoconus. The development of accelerated corneal crosslinking (A-CXL) protocols to shorten the treatment time has been hampered by the rapid depletion of stromal oxygen when higher UVA intensities are used, resulting in a reduced cross-linking effect. It is therefore imperative to develop better methods to increase the oxygen concentration within the corneal stroma during the A-CXL process. Photocatalytic oxygen-generating nanomaterials are promising candidates to solve the hypoxia problem during A-CXL. Biocompatible graphitic carbon nitride (g-C <subscript>3</subscript> N <subscript>4</subscript> ) quantum dots (QDs)-based oxygen self-sufficient platforms including g-C <subscript>3</subscript> N <subscript>4</subscript> QDs and riboflavin/g-C <subscript>3</subscript> N <subscript>4</subscript> QDs composites (RF@g-C <subscript>3</subscript> N <subscript>4</subscript> QDs) have been developed in this study. Both display excellent photocatalytic oxygen generation ability, high reactive oxygen species (ROS) yield, and excellent biosafety. More importantly, the A-CXL effect of the g-C <subscript>3</subscript> N <subscript>4</subscript> QDs or RF@g-C <subscript>3</subscript> N <subscript>4</subscript> QDs composite on male New Zealand white rabbits is better than that of the riboflavin 5'-phosphate sodium (RF) A-CXL protocol under the same conditions, indicating excellent strengthening of the cornea after A-CXL treatments. These lead us to suggest the potential application of g-C <subscript>3</subscript> N <subscript>4</subscript> QDs in A-CXL for corneal ectasias and other corneal diseases.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2041-1723
Volume :
15
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
38951161
Full Text :
https://doi.org/10.1038/s41467-024-49645-8